1999
DOI: 10.1016/s0006-3223(99)00036-0
|View full text |Cite
|
Sign up to set email alerts
|

Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
34
1

Year Published

2007
2007
2015
2015

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 41 publications
(40 citation statements)
references
References 34 publications
5
34
1
Order By: Relevance
“…39,40 In addi tion, decreased PLCβ1 expression in the brains of patients with schizophrenia, particularly in the DLPFC, has suggested the possible pathogenic involvement of PLCβ1 in schizo phrenia. 13,14,21 Here, using mPFClimited, shRNAmediated silencing of PLCβ1, we generated a mouse model that mimics the decrease of PLCβ1 in the DLPFC of patients with schizophrenia. Behavioural characterization of these model mice revealed that mPFCspecific knockdown of PLCβ1 induced only the impaired working memory phenotype without producing the altered anxiety or other schizophrenia endophenotypes previously observed in PLCβ1 −/− mice.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…39,40 In addi tion, decreased PLCβ1 expression in the brains of patients with schizophrenia, particularly in the DLPFC, has suggested the possible pathogenic involvement of PLCβ1 in schizo phrenia. 13,14,21 Here, using mPFClimited, shRNAmediated silencing of PLCβ1, we generated a mouse model that mimics the decrease of PLCβ1 in the DLPFC of patients with schizophrenia. Behavioural characterization of these model mice revealed that mPFCspecific knockdown of PLCβ1 induced only the impaired working memory phenotype without producing the altered anxiety or other schizophrenia endophenotypes previously observed in PLCβ1 −/− mice.…”
Section: Discussionmentioning
confidence: 99%
“…4,[9][10][11][12] Moreover, decreased expression of PLCβ1 has been detected in the brains of patients with schizophrenia. [13][14][15][16][17][18] Schizophrenia symptoms are categorized into 3 major types 19,20 -positive, negative and cognitive -and a majority of these symptoms have been observed as endophenotypes in PLCβ1null (PLCβ1 −/− ) mice. [9][10][11][12] These symptoms include increased locomotion, impaired social behaviour, impaired prepulse inhibition (PPI), and impaired working memory.…”
Section: Introductionmentioning
confidence: 99%
“…PLC-b1 has been shown to have altered expression in schizophrenic individuals. 26 Moreover, the PLC-b1 null mutation disrupts signaling through multiple pathways implicated in schizophrenic pathogenesis, such as the muscarinic cholinergic pathways, resulting in a comprehensive behavioral phenotype which correlates with that observed in the human condition. [68][69][70][71][72] We show that this mouse model exhibits numerous endophenotypes characteristic of schizophrenia including locomotor hyperactivity, sensorimotor gating deficits and cognitive deficits.…”
Section: Camentioning
confidence: 96%
“…[23][24][25] It is, therefore, significant that PLC-b1 represents a point of convergence for these signaling pathways and that levels of the protein have been shown to be altered in the cortex of chronic schizophrenic patients, increasing in the prefrontal cortex and decreasing in the superior temporal gyrus. 26 The outcomes of disrupted PLC-b1 signaling can be studied in PLC-b1 knockout (KO) mice, 9 which have been shown to have abnormal cortical maturation including aberrant barrel formation in the somatosensory cortex 3 as well as disrupted synapse formation and dendritic spine morphology. 27 Behaviorally, spatial memory deficits have been identified 28,29 but a more complete behavioral phenotype has not yet been established.…”
Section: Introductionmentioning
confidence: 99%
“…Brain tissue samples were prepared as described previously (Lin et al, 1999). Proteins were electrophoresed in a 15% SDS-polyacrylamide gel (5 mg/lane).…”
Section: Western Blot Analysis and 3 H-ketanserin Binding Assaymentioning
confidence: 99%